• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Current Front-Line Targeted Treatments in Ph+ ALL

Opinion
Video

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Related Videos
"Integrating New PAH Therapies into Clinical Practice"
"Clinical Evidence for Emerging PAH Therapies"
Screenshot of Angela Jia, MD, PhD, during a video interview
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Screenshot of Yuzhi Wang, MD, in a video interview
Dr Chris Pagnani
Stephanie L. Graff, MD, an expert on breast cancer
Stephanie L. Graff, MD, an expert on breast cancer
Video 13 - "Individualized Therapy for Specific Infections Associated with Bronchiectasis"
Michael Morse, MD, Duke University Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.